PZRXQ (PhaseRx) Total Inventories: $0.00 Mil (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PhaseRx Total Inventories?

PhaseRx PZRXQ -99.00% Total Inventories is $0.00 Mil as of Sep. 2017.

PhaseRx's total inventories for the quarter that ended in Sep. 2017 was $0.00 Mil. PhaseRx's average total inventories from the quarter that ended in Jun. 2017 to the quarter that ended in Sep. 2017 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. PhaseRx's Net-Net Working Capital per share for the quarter that ended in Sep. 2017 was $-0.09.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


PhaseRx  (OTCPK:PZRXQ) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

PhaseRx's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2017 is

Net-Net Working Capital Per Share (Q: Sep. 2017 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(5.257+0.75 * 0+0.5 * 0-6.339
-0-0)/11.690
=-0.09

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PhaseRx's Days Inventory for the three months ended in Sep. 2017 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2017 )/Cost of Goods Sold (Q: Sep. 2017 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

PhaseRx's Inventory Turnover for the quarter that ended in Sep. 2017 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2017 ) / Average Total Inventories (Q: Sep. 2017 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PhaseRx's Inventory to Revenue for the quarter that ended in Sep. 2017 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2017 ) / Revenue (Q: Sep. 2017 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


PhaseRx Total Inventories Related Terms


PhaseRx Total Inventories Historical Data

* Premium members only.

The historical data trend for PhaseRx's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhaseRx Total Inventories Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Total Inventories
0.00 0.00 0.00

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PhaseRx Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
PhaseRx (PZRXQ) has a Total Inventories of $0.00 Mil as of Sep. 2017. The total amount of inventory as recorded on a company's balance sheet. View historical data for PhaseRx and its competitors.
Is PhaseRx's Total Inventories too high?
PhaseRx's current Total Inventories is $0.00 Mil.
How does PhaseRx's Total Inventories compare to NSPX and HSTC?
PhaseRx's Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for PhaseRx and its competitors. PhaseRx's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhaseRx stock overvalued right now?
PhaseRx (PZRXQ) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For PhaseRx (PZRXQ), the current Total Inventories is $0.00 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PhaseRx Business Description

Address 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.